Manulife is trying to get paid as an Asia-and-wealth compounder while the market still treats the equity as a Canadian life insurer with a long-term care hangover. The second-quarter results support the mix-shift story more than they close the debate. Asia again supplied the growth, wealth and asset management expanded its fee margin, and management announced a third long-term care reinsurance. What the print does not settle is whether that progress is enough to lift core return on equity from the mid-teens toward the 18% objective without another capital-liberating deal.
Converted core earnings were about $1.4 billion. That is a 12% constant-currency advance from the year-ago quarter. Net income attributed to shareholders was higher still, helped by a market-experience gain after a first-quarter loss. Annualized-premium sales rose 21% and new-business contractual service margin rose 16%. Canada core earnings fell, and wealth-management net inflows shrank to a thin slice as retirement and retail outflows ate institutional wins from the CQS and Comvest books.
The Munich Re transaction covers biometric risk on a mid-single-digit-billion reserve block and is designed to cut cumulative long-term-care morbidity sensitivity by 24% once it closes. Unlike the earlier Global Atlantic and RGA deals, this one is largely capital-neutral. The next few prints therefore have to show that Asia new-business value can keep pace with sales, that Canadian group-insurance claims stop leaking, and that wealth-management flows stabilize. The open question is whether the current multiple already assumes that path, or whether the equity is still priced as if the legacy book defines the franchise.